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838 The Journal of Thoracic and CardioBackground: The aim of this prospective randomized trial was to evaluate the
efficacy of 3 intraoperative warming systems (Warm-Touch, Thermamed Smart-
Care OP system, and Allon 2001) on maintenance of normothermia and to inves-
tigate their effects on perioperative bleeding and transfusion requirements in pa-
tients undergoing off-pump coronary artery bypass grafting.
Methods: With institutional approval/patient informed consent, 90 patients present-
ing for elective multiple off-pump coronary artery bypass grafting were randomly
assigned to 1 of the 3 warming systems. Active warming was started after the
induction of anesthesia. Perioperative transfusion was based on international guide-
lines. Body core temperature was recorded every 30 minutes during operation.
Perioperative blood loss, autotransfusion, and allogenic transfusions were recorded.
Analysis of variance was performed with post hoc Scheffé tests and 2 tests.
Results: Normothermia could be sufficiently maintained during operation by the Allon
2001 only. Final body core temperature was 34.7°C 0.9°C (Warm-Touch), 35.6°C
0.8°C (Thermamed SmartCare OP), and 36.5°C  0.4°C (Allon 2001; P  .001,
Warm-Touch vs Thermamed SmartCare OP, Warm-Touch vs Allon 2001, and Ther-
mamed SmartCare OP vs Allon 2001). Perioperative blood loss was 2683  1049 mL
(Warm-Touch), 2300  788 mL (Thermamed SmartCare OP), and 1497  497 mL
(Allon 2001; P  .195, Warm-Touch vs Thermamed SmartCare OP; P  .001,
Warm-Touch vs Allon 2001; P  .001, Thermamed SmartCare OP vs Allon 2001).
Transfusion requirements were 1097  874 mL (Warm-Touch), 986  744 mL
(Thermamed SmartCare OP), and 431 387 mL (Allon 2001; P .838, Warm-Touch
vs Thermamed SmartCare OP; P  .003, Warm-Touch vs Allon 2001; P  .013,
Thermamed SmartCare OP vs Allon 2001). Free of allogenic transfusion were 15
(51.7%; Warm-Touch), 18 (60%; Thermamed SmartCare OP), and 24 (82.8%; Allon
2001) patients (P  .037).
Conclusions: The goal of normothermia during off-pump coronary artery bypass
grafting was best achieved by the Allon system. With this concept, overall blood loss
and transfusion requirements were reduced, hence indicating improved quality of
perioperative care.
Perioperative disturbances of hemostasis resulting in increased periop-erative bleeding and transfusion requirements are common complica-tions in patients undergoing cardiac operations.1 Use of cardiopulmo-nary bypass is a major risk factor.2 With the resurgence of theoff-pump technique for coronary artery bypass grafting (OPCABG),reduced perioperative bleeding and reduced use of blood products
could be demonstrated.3 However, according to our clinical experience, still a
considerable number of patients had to be given transfusions. One important reason
for this finding may be the development of severe perioperative hypothermia during
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ETOPCABG, because hypothermia may impair coagulation
pathways.4-6 Different systems to control intraoperative hy-
pothermia are available. Patients can be warmed with a
convective air warming system7 (Warm-Touch system;
Mallinckrodt Inc, St Louis, Mo) by using a total body
garment before OPCABG and a sterile lower body blanket
until the end of the operation after the preparation of venous
grafts. With resistive heating electric carbon-fiber blankets8
(Thermamed SmartCare OP system; Medeqco, Bad Oeyn-
hausen, Germany), the upper extremities can be completely
covered and the neck, body trunk, and lower extremities can
be partially covered for warming during OPCABG. Finally,
a disposable circulating-water warming garment9 (Allon
2001 system; MTRE Advanced Technologies Ltd, Or-
Akiva Industrial Park, Israel) can be wrapped around the
patient’s body, covering the back and upper parts of the
extremities. The aim of this prospective randomized trial
was to evaluate the efficacy of the 3 intraoperative warming
systems on maintenance of normothermia, their effects on
perioperative bleeding, their associated transfusion require-
ments, and costs during OPCABG.
Patients and Methods
This study was performed with institutional approval and patient
informed consent. Ninety patients were admitted to the study
according to the following criteria: (1) elective multiple OPCABG,
(2) preserved left ventricular function (ejection fraction 40%),
(3) absence of platelet glycoprotein inhibitor therapy, (4) exclusion
of preexisting coagulation disorders, (5) preoperative hematocrit
30% or higher, and (6) preoperative normothermia.
On the day before operation, after the routine preoperative visit,
the patients were assigned to 1 of the 3 intraoperative warming
systems by a computer-generated randomization list. According to
this list, the allocated warming system was prepared for the fol-
lowing day by the personnel responsible for patient positioning.
Upon arrival in the operating room, all patients were covered with
warmed sheets. After the induction of anesthesia, the different
warming devices were mounted, and active warming was started.
The Warm-Touch and Thermamed systems were both set to 42°C;
the Allon system was set to a 36.7°C body core temperature.
Operating room temperature was maintained at 22.2°C  0.9°C.
Body core temperature was recorded via rectal probe every 30
minutes during the operation and during the rewarming period in
the intensive care unit. An intraoperative fluid warmer (Astotherm
Plus; Cincinnati Sub-Zero Products Inc, Cincinnati, Ohio) set to
40°C was used for transfusions in all patients. Intraoperative
standard heparin therapy was reversed with protamine at the end of
the operation according to institutional standards. The periopera-
tive transfusion policy was based on international guidelines.10
The trigger for perioperative allogenic red blood cell transfusion
was a hematocrit of 25% or less. In all patients, autotransfusion
was performed (Continuous Auto Transfusion System; Fresenius
AG, Bad Homburg, Germany) during the operation. Perioperative
blood loss (assessed by cell-saving device suction and chest tube
drainage), the amount of autotransfusion, and the number of blood
product transfusions were recorded before transfer to the intensive
The Journal of Thoracicare unit and 24 hours after the operation. Hematocrit values and
coagulation profiles were recorded before, immediately after, and
24 hours after the operation. The durations of the operation, the
rewarming period (to reach 36.7°C), and mechanical ventilation
were noted in the postoperative period.
The primary outcome measures were body core temperature at
the end of the operation and maximal variations of intraoperative
body core temperature. The maximal intraoperative body core
temperature decrease was calculated as the difference between the
baseline and minimal core temperatures, and maximal increase
was calculated as the difference between the last intraoperative and
minimal core temperatures. Secondary outcome measures were
perioperative blood loss and transfusion requirements.
Cost analysis was performed for the 3 regimens on the basis of
list prices for the devices, disposable materials, and blood products
(direct costs are in US dollars). Costs of maintenance (ie, repairs)
or special conditions (ie, leasing contracts) were not included in
the calculation. Repayment for the different devices was calculated
for a 5-year period by extrapolating the results of this study to a
case load of 300 off-pump cases per year and considering red
blood cell transfusion requirements only.
Statistical analysis was performed with StatView 5.01 software
(SAS Institute Inc, Cary, NC). Analysis of variance with post hoc
Scheffé tests was performed for comparison of continuous data,
and 2 tests were performed for comparison of nominal data.
Unless otherwise stated, data are presented as mean  SD.
Results
Thirty patients were allocated to each intraoperative
temperature-management group. All patients had American
Society of Anesthesiologists status III. Demographic and
preoperative clinical data of the 90 patients are listed in
Table 1. Preoperative acetylsalicylic acid medication until
the day before operation was present in 86 patients (96%).
Two to 6 aortocoronary anastomoses (median, 4) were
performed in the study sample. The duration of operation
did not differ between groups (Table 2). Two patients
(2.2%) were excluded from the study protocol after random-
ization as a result of conversion to cardiopulmonary bypass
during the operation.
The intraoperative course of body core temperature
showed a significant difference among the 3 groups (Table
3). At the end of the intervention, patients were normother-
mic in the Allon group only. By contrast, mild and severe
hypothermia were observed in the Thermamed and Warm-
Touch groups, respectively. This resulted in a shortened
rewarming time and reduced postoperative ventilation time
for the Allon group compared with the other groups. The
duration of the intensive care unit stay was not significantly
different between groups (Table 2).
With normothermic perioperative blood loss, transfusion
of scavenged red blood cells and overall red blood cell
transfusions were reduced. The lowest total transfusion re-
quirements of allogenic red blood cells were observed for
the Allon group (Table 4). Free of allogenic transfusion
were 24 patients (82.8%) in the Allon group, 18 patients
c and Cardiovascular Surgery ● Volume 129, Number 4 839
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(60.0%) in the Thermamed group, and 15 patients (51.7%)
in the Warm-Touch group (P  .037). Perioperative admin-
istration of fresh frozen plasma was 410  570 mL (range,
0-1800 mL) in the Warm-Touch group, 310  449 mL
(range, 0-1200 mL) in the Thermamed group, and 103 
181 mL (range, 0-600 mL) in the Allon group (P  .682,
Warm-Touch vs Thermamed SmartCare OP; P  .033,
Warm-Touch vs Allon 2001; P  .206, Thermamed Smart-
Care OP vs Allon 2001). Small amounts of platelets were
transfused during the study period (Warm-Touch: 70 170
mL; range, 0-600 mL; Thermamed SmartCare OP: 80 
156 mL; range, 0-600 mL; Allon 2001: 10  56 mL; range,
0-300 mL; P  .961, Warm-Touch vs Thermamed Smart-
Care OP; P  .258, Warm-Touch vs Allon 2001; P  .159,
TABLE 1. Patient characteristics
Variable W
Age (y) 66.3 10.9
Male sex, n (%) 25 (83)
BMI (kg/m2) 27.8 3.9
EF (%) 57.7 12.5
EuroSCORE 5.6 3.8
Diabetes mellitus type II, n (%) 10 (33)
PAOD, n (%) 3 (10)
Renal disease, n (%) 8 (27)
W, Warm-Touch, T, Thermamed; A, Allon; BMI, body mass index; EF, left
are presented as mean  SD unless otherwise noted.
TABLE 2. Procedure times
Variable W (n  29) T (
Operation time (min) 232 65 248
Rewarming time (min) 288 96 214
Postoperative ventilation time (min) 701 226 600
Intensive care unit stay (d) 1.4 0.7 1.5
W, Warm-Touch; T, Thermamed; A, Allon. Data are presented as mean 
TABLE 3. Perioperative body core temperatures
Variable W (n  29)
Body core temperatures (°C)
Baseline 36.3 0.3
60 min after baseline 35.2 0.5
90 min after baseline 35.0 0.7
120 min after baseline 34.8 0.6
End of operation 34.7 0.9
Intraoperative temperature changes (°C)
Maximal temperature decrease 1.8  0.7
Maximal temperature increase 0.2  0.2
W, Warm-Touch; T, Thermamed; A, Allon; baseline, induction of anesthesia
as mean  SD.Thermamed SmartCare OP vs Allon 2001). Hematocrit
840 The Journal of Thoracic and Cardiovascular Surgery ● Aprivalues and coagulation profiles before and after surgery and
on the first postoperative day were comparable for the 3
groups (Table 5).
No burnings or decubitus were observed in this series of
patients. Two major sternal infections resulting in re-explora-
tion were recorded (1 case each in the Warm-Touch and
Thermamed groups). One of these patients had diabetes, and
the other was obese (body mass index, 37 kg/m2).
Acquisition costs and prices for disposables were higher
for the Allon system (device, US$12,100; 1-way wrap,
US$110) compared with the Thermamed system (device
and reusable blankets, US$5650) and the Warm-Touch sys-
tem (device, US$2160; 1-way garment, US$15). Cumula-
tive transfusion costs with the most expensive system (the
T A
64.4 10.7 65.6  11.8
24 (80) 23 (77)
27.9 3.1 27.5  2.8
59.5 14.4 57.8  13.1
4.9 2.8 5.6  3.2
8 (27) 8 (27)
2 (7) 1 (3)
10 (33) 8 (27)
cular ejection fraction; PAOD, peripheral arterial occlusive disease. Data
0) A (n  29) PW vs T PW vs A PT vs A
6 249 68 .423 .354 .991
04 82 101 .034 .001 .001
26 470 211 .943 .007 .018
.6 1.4 0.6 .978 .996 .993
 30) A (n  29) PW vs T PW vs A PT vs A
 0.3 36.2  0.3 .228 .699 .685
 0.5 36.0 0.6 .646 .001 .001
 0.6 36.1  0.5 .189 .001 .001
 0.8 36.2  0.5 .011 .001 .001
 0.8 36.5  0.4 .001 .001 .001
 0.5 0.6  0.4 .001 .001 .001
 0.3 1.0  0.5 .068 .001 .001
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ETfor the Thermamed system and US$18,654 for the Warm-
Touch system. Therefore, the lowest costs for the study
period could be obtained for the Thermamed system
(Warm-Touch, US$21,252; Thermamed SmartCare OP,
US$19,586; Allon 2001, US$20,000). Extrapolating costs
for a 5-year period and considering only the expenses for
the systems and the allogenic red blood cell transfusions, a
temperature management regimen with the Allon system
may be the least expensive (Warm-Touch, US$334,500;
Thermamed SmartCare OP, US$296,250; Allon 2001,
TABLE 4. Perioperative red blood cell transfusion require









510 631 (0–2400) 530
Intraoperative allogenic RBC
transfusion
200 328 (0–1200) 280
Postoperative allogenic RBC
transfusion
310 382 (0–1200) 250
Perioperative blood loss (mL) 2683 1049 2300
Intraoperative blood loss 1392 687 1345
Postoperative blood loss 1291 778 955
W, Warm-Touch; T, Thermamed; A, Allon; RBC, red blood cells. Data are
*Patients free of transfusion: W, 15 (51.7%); T, 18 (60%); and A, 24 (82.8)
TABLE 5. Perioperative laboratory parameters
Variable W (n  29) T (n  30)
Hematocrit (%)
Baseline 39.7 5.6 40.4 5.8
ICU 28.6 4.7 28.2 3.7
1st postop d 29.2 3.0 29.7 3.9
INR
Baseline 1.0 0.1 1.0 0.1
ICU 1.2 0.2 1.2 0.1
1st postop d 1.1 0.1 1.1 0.1
aPTT (s)
Baseline 36.9 4.9 37.3 5.7
ICU 39.3 8.3 40.1 9.7
1st postop d 39.1 5.7 38.8 7.9
Platelets (109/L)
Baseline 267 117 269 89
ICU 156 79 142 51
1st postop d 182 62 167 54
Fibrinogen (g/dL)
Baseline 346 112 319 141
ICU 218 80 228 93
1st postop d 271 65 294 102
W, Warm-Touch; T, Thermamed; A, Allon; baseline, induction of anesthes
operation; INR, international normalized ratio; aPTT, activated partial throUS$293,300).
The Journal of ThoraciDiscussion
Comparing 3 different warming systems, this trial demon-
strated that normothermia during OPCABG can best be
achieved by a circulating-water garment (the Allon thermo-
regulation system). The 2 other systems failed, although
studies have shown the efficacy of both the resistive heating
electric blanket (the Thermamed system) and forced air
warming (the Warm-Touch system) in the prevention of
perioperative hypothermia.7,8,11 Prolonged procedures (in-
duction of anesthesia, positioning, shaving, and the surgical
s and blood loss
30) A (n  29) PW vs T PW vs A PT vs A
4 431 387 .838 .003 .013
0 276 190 .168 .001 .042
9 (0–2100) 155 285 (0–900) .991 .055 .048
6 (0–1200) 104 224 (0–900) .677 .572 .159
8 (0–1200) 50 138 (0–600) .788 .014 .076
8 1497 497 .195 .001 .001
4 928  428 .954 .014 .031
1 566 243 .070 .001 .029
nted as mean  SD (range).
.037).
A (n  29) PW vs T PW vs A PT vs A
38.6 5.0 .743 .689 .267
28.3 3.9 .889 .502 .739
29.6 3.5 .995 .898 .855
1.0 0.2 .937 .905 .996
1.2 0.3 .581 .624 .682
1.1 0.1 .168 .193 .997
37.2 10.2 .502 .445 .988
38.8 11.1 .843 .826 .436
35.9 4.1 .987 .363 .416
280 52 .994 .863 .910
156 61 .709 .999 .693
172 42 .558 .769 .939
366 180 .863 .942 .681
245 104 .806 .322 .697
289 74 .558 .769 .938
, intensive care unit after the operation; 1st postop d, 24 hours after the










preseia; ICUprocedure), whole-body disinfection, and large areas of the
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complicate the prevention of hypothermia during OPCABG
compared with noncardiac operative interventions. The
circulating-water garment best covered the upper extremi-
ties and the back of the body. With the electric blankets,
roughly the same parts of the body could be wrapped,
whereas the forced air warming blankets could be mounted
to the lower part of the body only before and after harvest-
ing of the venous grafts.
The main benefit of successful maintenance of intraop-
erative body core temperature was a reduced perioperative
overall blood loss and a reduced total red blood cell trans-
fusion requirement. A significant reduction of allogenic red
blood cell transfusion volumes was observed only for the
comparison of the Allon and the Thermamed groups. Sam-
ple size in this study may be the reason that we found a
tendency for reduced allogenic red blood cell transfusion
only in the Allon group compared with the Warm-Touch
group. However, most importantly, the number of patients
receiving allogenic blood products could be significantly
decreased, hence reducing the risk of infection, transfusion
reactions, and immunosuppression related to the adminis-
tration of allogenic transfusions.10,12
Maintenance of intraoperative normothermia during car-
diac operations with cardiopulmonary bypass with the sup-
port of the Allon system has been shown to be favorable in
terms of reduced myocardial injury,13 enhanced cardiac
function, and increased hemodynamic stability.14 These
studies did not address the effects on hemostasis and trans-
fusion. Some investigations comparing hypothermic and
normothermic cardiopulmonary bypass results regarding
transfusion requirements have shown conflicting re-
sults.15-17 Performing OPCABG per se has been shown to
significantly reduce transfusion of allogenic blood prod-
ucts.3 The present data now indicate a further positive effect
on bleeding and transfusion requirements if normal body
core temperature can be maintained during OPCABG. This
effect of perioperative normothermia has previously been
reported for orthopedic18 and visceral19 surgical patients.
Surgical bleeding and, thus, coagulation during hypother-
mia may be influenced by reduced clotting factor activity,5
impaired platelet function,4 and activated fibrinolysis.6
Comparable prothrombin and activated partial thromboplas-
tin times for different body core temperatures, as in this
study, are not conflicting findings, because routine labora-
tory testing is performed at 37°C. Only temperature-
adjusted performance of these temperature-sensitive tests
may allow a correct assessment and reveal prolonged val-
ues.20
Today, improvement of patient outcomes at minimal cost
is a primary goal for most clinicians. This goal can some-
times be achieved only by a relatively high initial capital
expenditure. Conservative cost calculation for the different
842 The Journal of Thoracic and Cardiovascular Surgery ● Apriwarming systems and transfusion management based on the
study data gives reason to assume that improved patient
management is possible at balanced expenses with the most
expensive system. However, only direct costs were taken
into account in our calculation. Indirect costs were not
assessed: the cost effects of a reduced wound infection
rate21 and a significantly shortened postoperative rewarm-
ing and ventilation period, as demonstrated in this study, are
difficult to determine. For instance, the duration of the
postoperative ventilation period is biased by a variety of
factors, and postoperative normothermia is only one prereq-
uisite for successful endotracheal extubation. Finally, de-
spite the favorable results of improved intraoperative tem-
perature management, the risk of complications from the
different warming systems should be considered.22,23
In conclusion, this prospective study evaluating the effi-
cacy of 3 intraoperative warming systems during OPCABG
demonstrates that the goal of normothermia was best
achieved by the Allon system. With this system, perioper-
ative blood loss and transfusion requirements were reduced,
hence indicating improved quality of perioperative care.
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